The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD)
In-clinic AquaGold has a defensible role for high-stakes events and post-procedure boosts
semaglutide just happens to be their hot new product, and its much less expensive than the brand-name drugs
It works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
These medications are often discussed because they affect appetite, fullness, and blood sugar, but they can also affect how quickly the stomach empties
J Vet Pharmacol Therap